Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of HDM1005 injection in adults with obesity without diabetes
CTR20250184Phase 2Completed
- Sponsor
- 杭州中美华东制药有限公司 (Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.)
- Start
- Feb 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in obesity and Overweight comparing HDM1005 with Placebo (2 arms). Started Feb 2025; status: completed.
02
Drugs
poterepatide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on CTR20250184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250184.